The Market's Island of Misfit Toys: Grifters, AI Excuses, and Lawsuit Jackpots

Today we are looking at a bizarre grab-bag of market leftovers—the companies that didn't fit into any neat thematic buckets and were shoved into an unclassified miscellaneous pile. If you think this is just a random assortment of tickers, you are deeply mistaken. This group perfectly encapsulates everything that is dysfunctional, absurd, and occasionally brilliant about the 2026 market. We have companies blaming AI for their own mismanagement, cyclical retailers masquerading as crypto whales, and legacy material giants quietly eating the world. This is stupid, and here's why.

Block (XYZ.US) & Modine (MOD.US)

Let’s start with Jack Dorsey’s Block (XYZ.US), which continues its pressure-filled market run recently. In July 2026, they agreed to hand over $45 million to settle a multi-state probe into Cash App's deceptive practices. But the real kicker? Firing over 4,000 people in February and waving their hands about "advances in artificial intelligence." Please. Do not use AI as a smokescreen for bloated operations. With $24.2 billion in annual revenue, they should be doing better. Good luck with that.

Why aren't you moving faster toward actual structural growth? Look at Modine (MOD.US). While the Valley hallucinates about general AI, server racks are literally melting. Modine locked in a $4 billion multi-year capacity agreement in May 2026 to provide cooling solutions. Their Q4 fiscal 2026 net sales spiked 47% to $954.4 million, driving a massive year-to-date stock rally. Selling cold air to overheated data centers—that is where the real money is.

Eightco Holdings (ORBS.US) & Skillz (SKLZ.US)

Then we have the ultimate grift. Eightco Holdings (ORBS.US) claims to be an e-commerce inventory solution provider. Yet, if you look at their balance sheet as of July 2026, they are sitting on $406 million in assets stuffed with $90 million in indirect OpenAI equity, piles of Ethereum, and Worldcoin. A cyclical retailer moonlighting as a venture capitalist? The stock has been violently volatile this year, and rightly so. This is absurd.

Skillz (SKLZ.US) isn't much better. This mobile gaming platform pulled in a paltry $29.1 million in Q1 2026 revenue with a $10.9 million net loss. Their actual business model right now seems to be litigation. In April, they won a jaw-dropping $420 million jury verdict against a competitor, sparking a massive short-term rebound in the stock. When your legal department out-earns your product team, you have a fundamental problem.

Xunlei (XNET.US) & X Financial (XYF.US)

The Chinese tech diaspora here is equally messy. Xunlei (XNET.US) actually grew Q1 2026 revenues by 54.1% to $98.6 million. Sounds great, until you see the $192.4 million net loss because a long-term investment blew up. Slapping a $20 million stock buyback on that kind of capital destruction won't fix a fundamentally broken narrative, which is why the stock continues to underperform.

Over at X Financial (XYF.US), the fintech player is dealing with an exodus. Chief Risk Officer Yufan Jiang walked out the door in June 2026. If there is one person you do not want quitting a consumer lending platform in this regulatory climate, it is the risk guy. Unsurprisingly, the stock's recent trend has been notably weak.

CRH (CRH.US) & Molina Healthcare (MOH.US)

Let's talk about the boomers of the group. CRH (CRH.US) is a global building materials juggernaut. They dropped $8.5 billion to acquire Arcosa in June 2026 and posted $7.37 billion in Q1 revenue. Sure, the stock took a minor hit recently when treasury yields spiked, but they are generating massive, tangible value.

Molina Healthcare (MOH.US), on the other hand, is a government-sponsored health insurer operating on a razor-thin 0.42% net margin. They slashed their 2025 guidance in July and pegged 2026 EPS at just $5.000, sending the stock into a recent tailspin. Medical cost inflation is eating them alive.

Becton Dickinson & Co (BDX.US) & Twist Bioscience (TWST.US)

Finally, the healthcare innovators. Becton Dickinson & Co (BDX.US) is steadily climbing year-to-date, beating estimates with $4.71 billion in Q3 2026 revenue. They recently rolled out an AI-enabled pharmacy dispensing system in Europe. Everyone has to say "AI" now, but BDX actually has the hospital contracts to monetize it. Twist Bioscience (TWST.US), meanwhile, is still burning cash to print DNA on silicon. They continue to push their synthetic biology platform forward, but the stock remains a highly volatile roller coaster for investors waiting for sustained profitability.

My view is simple: Stop buying the buzzwords. The winners of 2026 are the ones building the physical infrastructure, not the ones hiding behind AI press releases or crypto hoards.

This article does not constitute investment advice.